A single-center retrospective study of dabrafenib plus trametinib combination therapy in patients with BRAF V600E-positive thyroid cancer
Dabrafenib plus trametinib combination therapy demonstrated clinical effectiveness in patients with BRAF V600E-positive thyroid cancer, with response rates comparable to those observed in clinical trials. However, tumor shrinkage did not appear to translate into improved survival in patients with ATC, highlighting the limitations of current targeted therapies in managing this aggressive subtype.
Authors
- Hisayuki Kato (ORCID: https://orcid.org/0000-0002-8101-7423)
- Tsutomu Ando
- Kenji Kawada (ORCID: https://orcid.org/0000-0003-4336-6937)
- Yuko Oya (ORCID: https://orcid.org/0000-0002-3171-6031)
- Kazuyoshi Imaizumi (ORCID: https://orcid.org/0000-0002-3790-8691)
- Yosuke Sasaki (ORCID: https://orcid.org/0000-0002-5290-4875)
- Yumi Tomiie
- Kimio Ogawa
- Tomoki Kuki
- Yatsuka Hibi
Institutions
- Fujita Health University (JP)
- Fujita Health University Hospital (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1007/s10147-025-02861-8
- Citations
- 3
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 3.88